20 Aug
2021

Legal challenges to the PTAB’s NHK-Fintiv discretionary denial regime mount

Legal challenges to the USPTO’s increased use of discretionary denial are mounting, and pharma companies – especially generic companies in Hatch-Waxman proceedings – will be affected significantly by their outcome

Adam Houldsworth

Author | Life sciences reporter

[email protected]

Adam Houldsworth